GlaxoSmithKline said it would begin a late-stage study of its Fluarix flu vaccine, which U.S. officials already have agreed to buy on an emergency basis to help ease the shortage of flu vaccine. GSK plans a 1,000-person trial in four U.S. locations this month and expects to submit an application to the FDA for approval of the vaccine next year. The U.S. announced earlier this week it would buy up to 4 million doses of the vaccine, produced at a plant in Germany.

Full Story:

Related Summaries